Published online Oct 26, 2023. doi: 10.4252/wjsc.v15.i10.979
Peer-review started: July 27, 2023
First decision: August 15, 2023
Revised: September 23, 2023
Accepted: October 17, 2023
Article in press: October 17, 2023
Published online: October 26, 2023
Processing time: 90 Days and 22.8 Hours
Fracture healing is accompanied by obvious tissue hypoxia, it is worth exploring the effects of hypoxia on periosteal stem cells (PSCs) osteogenic differentiation. However, the underlying mechanisms needs to be clarified.
RUNX family transcription factor 2 (RUNX2) is a key regulator of osteogenic differentiation, and studies have found that RUNX2 has osteogenic activity in bone marrow mesenchymal stem cells, but its role in the osteogenic differentiation pathway of PSCs is still unclear.
This study aimed to determine the effect of hypoxia on PSCs, and the expression of microRNA-584-5p (miR-584-5p) and RUNX family transcription factor 2 in PSCs was modulated to explore the impact of the miR-584-5p/RUNX2 axis on hypoxia-induced osteogenic differentiation of PSCs.
PSCs were extracted from 7-d-old C57BL/6J mice. Then, PSCs were stimulated them with hypoxia, and the characteristics and functional genes related to PSC osteogenic differentiation were measured.
Hypoxia promotes PSC osteogenic differentiation. Also, miR-584-5p upregulation affects hypoxia-induced PSC osteogenic differentiation and RUNX2 axis was targeted by miR-584-59. The upregulation of RUNX2 specifically reversed the inhibitory effect of miR-584-5p overexpression on the hypoxia-induced PSC osteogenic differentiation.
MiR-584-5p inhibited the hypoxia-induced PSC osteogenic differentiation via RUNX2.
MiR-584-5p inhibits hypoxia-induced osteogenic differentiation of PSC through RUNX2, and PSC has good osteogenic/chondrogenic differentiation potential. These results indicate that miR-584-5p/RUNX2 axis may be a key target pathway for bone repair and regeneration.
